On October 28th, we handed over an open letter to the Dutch Ministry of Health calling for increased transparency in the pharmaceutical sector. The letter was signed by numerous experts and organizations, including the Dutch Patient Federation and Doctors Without Borders Netherlands. The current lack of transparency is leading to inexplicably high medicine prices, which weigh heavily on healthcare budgets. Early next year we will also present the letter to the Dutch House of Representatives.
Report
14/9/2026
Unlocking the potential of socially responsible licensing of medical innovations
Wemos has published a guidance brief for the application of socially responsible licensing (SRL) of publicly funded medical innovations. With SRL, universities and other public research institutes can attach conditions when licensing medical innovations to private companies, helping to ensure that these innovations become affordable and accessible to everyone. Our guidance brief explores how SRL can be applied to secure that public investments in medical innovation deliver an optimal public return - without jeopardizing commercial incentives. Read more
